-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

733 Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial

Program: Oral and Poster Abstracts
Type: Oral
Session: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: New Treatment Approaches for AML
Hematology Disease Topics & Pathways:
Research, Clinical trials, Clinical Research
Monday, December 9, 2024: 10:30 AM

Daniel J. DeAngelo, MD, PhD1, Andre C. Schuh, MD, FRCPC2, Brian A. Jonas, MD, PhD3, Pamela S. Becker, MD, PhD4, Anjali S. Advani, MD5, Geoffrey L. Uy, MD6, Janusz Krawczyk, MD7, Harry P. Erba, MD, PhD8, Gabriel N Mannis, MD9, Chun Yew Fong, MBBS, FRACP, FRCPA, PhD10*, Florian Kuchenbauer, MD, PhD, FRCPC11, Mary-Elizabeth M. Percival, MD12, Jane L. Liesveld, MD13, William Blum, MD14, Brenda W Cooper, MD15, Alice Mims, MD16, Francesco Lanza, MD17,18*, Jeroen J.W.M. Janssen19, Juan Miguel Bergua Burgues, MD20*, Tibor Kovacsovics, MD21*, Norbert Vey, MD22, Martina V. Hemmer, MA23*, Gaetano Bonifacio, MD23*, Edwin Rock, MD, PhD23 and Pau Montesinos, PhD, MD24*

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
2Department of Medical Oncology and Hematology, University Health Network- University of toronto, Toronto, ON, Canada
3UC Davis Comprehensive Cancer Center, Davis, CA
4Hematology/HCT, City of Hope, Duarte, CA
5Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
6Washington University School of Medicine, Saint Louis
7Department of Haematology, University Hospital Galway, H91 Galway, Ireland; National University of Ireland, H91, Galway, Ireland
8Duke University Cancer Institute, Durham, NC
9Stanford, Stanford Cancer Center, Menlo Park, CA
10Department of Hematology, Austin Health, Heidelberg, VIC, Australia
11Leukemia/Bone Marrow Transplant Program of British Columbia, British Columbia Cancer Agency, Vancouver, Canada
12Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA
13Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY
14Emory University, Winship Cancer Institute, Atlanta, GA
15Department of Hematology and Stem Cell Transplant, University Hospitals Seidman Cancer Center, Cleveland, OH
16The Ohio State University Comprehensive Cancer Center, Columbus, OH
17Division of Hematology, Onco-hematologic Department, AUSL della Romagna, Ravenna, Italy
18Hematology Unit and Metropolitan Romagna Transplant Network, University of Bologna, Ravenna, Italy
19Department of Hematology, Amsterdam University Medical Centers, VUmc, Amsterdam, Netherlands
20Hospital San Pedro de Alcántara, Caceres, Spain
21City of Hope Phoenix, Goodyear, AZ
22Paoli-Calmette Cancer Institute, Marseille, France
23GlycoMimetics, Inc., Rockville, MD
24Hematology, Hospital Universitari I Politécnic La Fe and Programa Español de Tratamientos en Hematología (PETHEMA) Group, Valencia, Spain

Introduction: Uproleselan (GMI-1271) is an E-selectin antagonist that disrupts AML cell survival pathways, overcomes chemotherapy resistance, and potentially deepens chemotherapy response. Phase 2 data demonstrated uproleselan efficacy in patients with relapsed/refractory (R/R) and in >60 yrs newly diagnosed (ND) acute myeloid leukemia (AML) (DeAngelo et al., Blood 2022). This Phase 3 international, randomized, double-blind, placebo (PBO)-controlled trial assessed uproleselan with chemotherapy versus chemotherapy alone in R/R AML (NCT03616470). An NCTN sponsored trial (NCT03701308) in the ND population is ongoing.

Methods: Eligibility included patients age 18-75 yrs, R/R patients with AML in first or second untreated relapse and fit for chemotherapy. Randomization was 1:1, stratified by age, disease status (primary refractory/early relapse ≤6 months, late relapse >6 months), and FAI or MEC chemotherapy. Uproleselan or PBO was given during induction and up to 3 consolidation cycles. The primary endpoint was overall survival. Key secondary endpoints included severe oral mucositis during induction, complete remission (CR), and remission (CR/CRh) rates. Overall, 388 patients were enrolled (N=385 dosed) in the trial at 59 sites in North America, Europe, and Australia. Due to fewer than expected death events, we report results of a time-based primary analysis (31March2024) with a median follow-up time of 37.9 months.

Results: Treatment arms were well-balanced: median age, 58.0 (range 20-75); median number of prior lines of therapy, 1.0 (range 1-4); primary refractory cases, 33%; European LeukemiaNet 2017 (ELN) adverse risk, 41.5%. Median OS (mOS) was 13.0 months for uproleselan and 12.3 months for PBO (p=0.39; HR=0.89, 95% CI 0.69-1.15), with survival probabilities at 48 months for uproleselan and PBO of 34.1% and 25.5%, respectively. Rates of severe (Grade ≥3) oral mucositis during induction were equal across arms (7.2%) while CR and CR/CRh rates trended in favor of uproleselan (36.1% vs 33.5% [p=0.62] and 46.4% vs 41.2% [p=0.24]). Of patients achieving CR, a greater proportion receiving uproleselan achieved MRD negativity (67.1% vs 61.5 %). Post-treatment allogeneic stem cell transplant (allo-SCT) rates were comparable between arms (N=101, 52.1% vs N=99, 51.0%). In patients achieving allo-SCT, mOS was Not Reached (NR) on uproleselan vs 24.8 months in PBO arm (HR=0.59, 95% CI 0.38 – 0.91).

Patients with primary refractory AML (N=128, 33%), a pre-specified subgroup, had mOS of 31.2 months on uproleselan (N=62) versus 10.1 months on PBO (N= 66) (HR=0.58; 95% CI 0.37-0.91). Survival in the PBO group is consistent with historical outcomes in this setting (Ferguson, 2016). Uproleselan survival benefit in primary refractory disease was agnostic to backbone chemotherapy (MEC= HR 0.68, 95% CI 0.34-1.38; FAI= HR 0.53, 95% CI 0.30-0.93). Complete response rates for primary refractory disease trended in favor of uproleselan over PBO (32.3% vs 27.3%). However, responses to uproleselan may potentially be deeper, as indicated by median duration of response (DoR) not being reached for primary refractory patients treated with uproleselan, compared to a median DoR of 12.7 months in the PBO arm (HR 0.26, 95% CI 0.09 – 0.75). Clinically meaningful activity was also seen in primary refractory patients who achieved MRD- status [uproleselan, N=22 (35.5%) vs. PBO, N=16 (24.2%)] (mOS: NR vs. 14.7 months, HR 0.07, 95% CI 0.02 – 0.35) or achieved allo-SCT [uproleselan, N=37 (59.7%) vs PBO, N=34 (51.5%)] (mOS: NR vs. 19.7 months, HR 0.34, 95% CI 0.17 – 0.69). Of patients transplanted, survival probabilities at 60 months for uproleselan and PBO were 57.5% vs 27.7%, respectively. Treatment-emergent adverse events (TEAEs), Serious Adverse Events (SAEs), grade 3 or higher TEAEs were similar across study arms in both Intent to Treat (ITT) and primary refractory populations. There was no discernible added toxicity with uproleselan treatment over chemotherapy alone.

Conclusions: Although this Phase 3 trial did not meet its primary OS endpoint for the ITT population, these clinical data provide compelling evidence of uproleselan efficacy in patients with primary refractory AML without additional toxicity. In primary refractory AML, a mOS of 31.2 months highlights the potential of uproleselan to significantly improve treatment outcomes in this high unmet medical need population.

Disclosures: DeAngelo: Servier: Consultancy, Honoraria, Research Funding; Daiichi-Sankyo: Other: DSMB; Novartis: Consultancy, Research Funding; Blueprint: Consultancy, Research Funding; AbbVie: Research Funding; Jazz: Consultancy; Kite: Consultancy; Curis: Consultancy; MT Sinai MPN Consortium: Other: DSMB; Pfizer: Consultancy; Amgen: Consultancy, Honoraria; Autolos: Consultancy; Glycomimetics: Research Funding; Takeda: Consultancy; Incyte: Consultancy; Fibrogen: Other: DSMB; Gilead: Consultancy; Bristol-Meyers Squibb: Honoraria. Jonas: Forty-Seven: Research Funding; Forma Therapeutics: Research Funding; F. Hoffman-La Roche: Research Funding; Celgene: Research Funding; Aptose: Research Funding; AROG: Research Funding; Amgen: Research Funding; Rigel: Consultancy, Other: Travel; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; Servier: Consultancy, Membership on an entity's Board of Directors or advisory committees; Kymera: Consultancy, Membership on an entity's Board of Directors or advisory committees; GlycoMimetics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Genentech/Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Daiichi-Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Hanmi: Research Funding; Immune-Onc: Research Funding; Incyte: Research Funding; Jazz: Research Funding; Loxo Oncology: Research Funding; Pharmacyclics: Research Funding; Sigma Tau: Research Funding; Treadwell: Research Funding. Advani: MJH Life: Honoraria; Glycomimetics: Research Funding; Amgen: Research Funding; Wiley: Honoraria; Kite: Consultancy, Research Funding; Immunogen: Research Funding; Web MD: Honoraria; Emmes: Honoraria; MD Education: Honoraria; Incyte: Research Funding; BEAM: Other: Research support, Research Funding; Seattle Genetics: Research Funding; American Society of Hematology: Honoraria; Pfizer: Other: Manuscript help, Research Funding; Wolters Kluwer: Honoraria; Springer: Honoraria; PER: Honoraria; Servier: Research Funding; Macrogenics: Research Funding; OBI: Research Funding; Kura: Research Funding; Novartis: Consultancy. Krawczyk: Health Research Board, Ireland: Research Funding; University of Galway: Current Employment. Erba: Daiichi Sankyo: Honoraria. Mannis: Gilead: Research Funding; Glycomimetics: Research Funding; Aptose: Research Funding; Genentech: Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Rigel: Membership on an entity's Board of Directors or advisory committees; Astellas: Membership on an entity's Board of Directors or advisory committees; Agios: Consultancy, Membership on an entity's Board of Directors or advisory committees; Macrogenics: Consultancy; Astex: Research Funding; Stemline: Consultancy, Membership on an entity's Board of Directors or advisory committees; Forty Seven: Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS/Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Syndax Pharmaceuticals, Inc.: Research Funding; Immunogen: Membership on an entity's Board of Directors or advisory committees; Jazz: Research Funding; ImmuneOnc: Research Funding; Servier: Consultancy, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy; Wugen: Membership on an entity's Board of Directors or advisory committees; Orbital Therapeutics: Membership on an entity's Board of Directors or advisory committees. Fong: Adaptive Biotech: Membership on an entity's Board of Directors or advisory committees; BeiGene: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Otsuka: Membership on an entity's Board of Directors or advisory committees; Jazz: Membership on an entity's Board of Directors or advisory committees; Novotech: Consultancy; Servier: Speakers Bureau; BMS: Speakers Bureau; Astella: Speakers Bureau; AbbVie: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Percival: Trillium: Research Funding; VinceRx: Research Funding; Telios: Research Funding; Abbvie: Research Funding; Pfizer: Research Funding; Oscotec: Research Funding; Nohla Therapeutics: Research Funding; Immunogen: Research Funding; Glycomimetics: Research Funding; Cardiff Oncology: Research Funding; BMS/Celgene: Research Funding; Biosight: Research Funding; Astex: Research Funding; Ascentage: Research Funding. Liesveld: Syros: Membership on an entity's Board of Directors or advisory committees; Servier: Membership on an entity's Board of Directors or advisory committees; Dalichi Sankyo: Membership on an entity's Board of Directors or advisory committees. Mims: Daiichi Saynko: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Leukemia and Lymphoma Society Beat AML Study: Other: Senior Medical Director; BMS: Membership on an entity's Board of Directors or advisory committees; Treadwell Therapeutics: Membership on an entity's Board of Directors or advisory committees; Foghorn Therapeutics: Membership on an entity's Board of Directors or advisory committees. Janssen: Abbvie: Other: Advisory Board; Novartis: Other: Advisory Board, Research Funding; BMS: Research Funding. Kovacsovics: NeoGenomics Laboratories: Membership on an entity's Board of Directors or advisory committees; Takeda Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Astellas Pharma: Membership on an entity's Board of Directors or advisory committees; Servier Laboratories: Honoraria; Rigel Pharmaceuticals, Inc.: Honoraria, Membership on an entity's Board of Directors or advisory committees; Syndax Pharmaceuticals, Inc.: Other: institutional research support; GlycoMimetics, Inc.: Other: institutional research support; Gilead Sciences, Inc.: Other: institutional research support; Amgen: Other: institutional research support; AbbVie: Other: institutional research support. Hemmer: GlycoMimetics, Inc.: Current Employment. Bonifacio: GlycoMimetics, Inc.: Current Employment. Rock: GlycoMimetics, Inc.: Current Employment. Montesinos: Kura Oncology: Consultancy; Astellas: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: research support, Speakers Bureau; Syndax: Consultancy; Glycomimetics: Consultancy; Daiichi Sankyo, Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: research support, Research Funding, Speakers Bureau; Servier: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: research support, Research Funding, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Other: research support, Speakers Bureau; Novartis: Consultancy, Research Funding, Speakers Bureau; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: research support, Research Funding, Speakers Bureau; Jazzpharma: Consultancy, Research Funding, Speakers Bureau; Pfizer: Consultancy, Research Funding, Speakers Bureau.

Previous Abstract | Next Abstract >>
*signifies non-member of ASH